A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Type 1 Diabetes, Obesity, Overweight

In brief

The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.

Key facts

Study ID

NCT06914895

Run by

Eli Lilly and Company

People needed

905

Starts

2025-04-25

Expected to finish

2026-12-01

Last updated by the study team

2026-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have type 1 diabetes and on insulin treatment for at least one year prior to screening
• Have an HbA1c value of 7.0% to 10.5% inclusive, at screening
• Have a body mass index (BMI) of ≥25 kilograms per square meter (kg/m2) at screening
• Are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study

You may not qualify if…

• Have experienced two or more events requiring hospitalization due to poor glucose control (hyperglycemia or (diabetic ketoacidosis (DKA)) during the period of 180 days prior to screening and until randomization.
• Have experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization.
• Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
• Have had chronic or acute pancreatitis
• Have used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening

Where it is running

• Care Access - Santa Clarita — Santa Clarita, California, United States
• University of Colorado Anschutz Medical Campus — Aurora, Colorado, United States
• Atlanta Diabetes Associates — Atlanta, Georgia, United States
• Orita Clinical Research — Decatur, Georgia, United States
• North Georgia Clinical Research — Woodstock, Georgia, United States
• East-West Medical Research Institute — Honolulu, Hawaii, United States
• Rocky Mountain Clinical Research — Idaho Falls, Idaho, United States
• Southern Illinois University School of Medicine — Springfield, Illinois, United States
• Indiana University Health University Hospital — Indianapolis, Indiana, United States
• Iowa Diabetes and Endocrinology Research Center — West Des Moines, Iowa, United States
• Endocrine and Metabolic Consultants — Rockville, Maryland, United States
• HealthPartners Institute dba International Diabetes Center — Minneapolis, Minnesota, United States
• SKY Integrative Medical Center/SKYCRNG — Ridgeland, Mississippi, United States
• Boeson Research MSO — Missoula, Montana, United States
• Palm Research Center Tenaya — Las Vegas, Nevada, United States
• Palm Research Center Sunset — Las Vegas, Nevada, United States
• Albany Medical College, Division of Community Endocrinology — Albany, New York, United States
• Research Foundation of SUNY - University of Buffalo — Buffalo, New York, United States
• NYC Research — New York, New York, United States
• SUNY Upstate Medical University — Syracuse, New York, United States
• Lucas Research, Inc. — Morehead City, North Carolina, United States
• Care Access - Lima — Lima, Ohio, United States
• Alliance for Multispecialty Research, LLC — Norman, Oklahoma, United States
• Suburban Research Associates — West Chester, Pennsylvania, United States
• Sansum Diabetes Research Institute — Santa Barbara, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.